{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:46:08Z","timestamp":1782499568524,"version":"3.54.5"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1210548"],"award-info":[{"award-number":["OPP1210548"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-002454"],"award-info":[{"award-number":["INV-002454"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-062291"],"award-info":[{"award-number":["INV-062291"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>As programs for azithromycin mass drug administration (AZ-MDA) to reduce child mortality have begun in some parts of West Africa, it is imperative to understand their financial costs. We combined a micro-costing framework and observations from an implementation-focused sub-study within the AVENIR trials in 80 communities in the Dosso region of Niger to estimate the national health sector financial costs of a scaled-up programmatic approach for azithromycin biannual distribution to children aged 1\u201359 months of age living in nonurban areas, using the door-to-door modality. Our outcomes of interest were the annual budget at the regional and national levels for Niger and the cost per dose delivered. We found that the annual national budget required for AZ-MDA achieving 90% average coverage would be $12.5 million (M) (95% Uncertainty Interval (UI) $12.2M, $13.0M) translating to $1.59 (95% UI $1.40, $2.30) per dose delivered. Across regions, cost per dose would vary from $1.17 (95% UI $1.03, $1.69) to $3.61 (95% UI $3.20, $5.16), with higher cost per dose expected for more sparsely populated regions. Training costs represented a large fraction (16.4%) of total costs, and integration of training with that for existing health interventions may provide opportunities for efficiency.<\/jats:p>","DOI":"10.1371\/journal.pgph.0006039","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:48:46Z","timestamp":1782496126000},"page":"e0006039","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8815-1642","authenticated-orcid":true,"given":"Brittany","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laminou Maliki","family":"Haroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farissatou","family":"Oumarou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Arzika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramatou","family":"Maliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdou","family":"Amza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamba","family":"Alio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bawa","family":"Aichatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7711-6938","authenticated-orcid":true,"given":"Ismael Issa","family":"Sara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diallo","family":"Beidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-7233","authenticated-orcid":true,"given":"James G.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1723-7085","authenticated-orcid":true,"given":"Stefano M.","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin F.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran S.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-2668","authenticated-orcid":true,"given":"Meagan C.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the AVENIR Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"2","key":"pgph.0006039.ref001","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(21)00515-5","article-title":"Global, regional, and national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation","volume":"10","author":"D Sharrow","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"10108","key":"pgph.0006039.ref002","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/S0140-6736(17)31758-0","article-title":"Mapping under-5 and neonatal mortality in Africa, 2000-15: a baseline analysis for the Sustainable Development Goals","volume":"390","author":"N Golding","year":"2017","journal-title":"Lancet"},{"key":"pgph.0006039.ref003","volume-title":"World Health Statistics 2016: Monitoring Health for the SDGs, Sustainable Development Goals","author":"World Health Organization","year":"2016"},{"issue":"17","key":"pgph.0006039.ref004","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa1715474","article-title":"Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa","volume":"378","author":"JD Keenan","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"pgph.0006039.ref005","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1817213","article-title":"Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa","volume":"380","author":"JD Keenan","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"pgph.0006039.ref006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4269\/ajtmh.18-0846","article-title":"Mass Azithromycin Distribution to Prevent Childhood Mortality: A Pooled Analysis of Cluster-Randomized Trials","volume":"100","author":"CE Oldenburg","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"pgph.0006039.ref007","volume-title":"WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival","author":"World Health Organization","year":"2020"},{"issue":"1","key":"pgph.0006039.ref008","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1186\/s12889-021-10824-7","article-title":"Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR)","volume":"21","author":"KS O\u2019Brien","year":"2021","journal-title":"BMC Public Health"},{"issue":"8","key":"pgph.0006039.ref009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa2312093","article-title":"Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial","volume":"391","author":"KS O\u2019Brien","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"pgph.0006039.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002559","article-title":"Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trial","volume":"3","author":"AM Arzika","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"pgph.0006039.ref011","volume-title":"Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on Neglected Tropical Diseases","author":"World Health Organization","year":"2015"},{"issue":"12","key":"pgph.0006039.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005037","article-title":"Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application","volume":"10","author":"C Fitzpatrick","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pgph.0006039.ref013","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1179\/2047773211Y.0000000010","article-title":"Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria","volume":"105","author":"D Evans","year":"2011","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"pgph.0006039.ref014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/heapol\/czm041","article-title":"Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up","volume":"23","author":"S Brooker","year":"2008","journal-title":"Health Policy Plan"},{"issue":"10","key":"pgph.0006039.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001362","article-title":"The cost of antibiotic mass drug administration for trachoma control in a remote area of South Sudan","volume":"5","author":"JH Kolaczinski","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pgph.0006039.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004893","article-title":"Costs and cost-effectiveness of community health worker programs on reproductive, maternal, newborn and child health in low- and middle-income countries (2015-2024): A scoping review","volume":"6","author":"M Miyares","year":"2026","journal-title":"PLOS Glob Public Health"},{"key":"pgph.0006039.ref017","year":"2023"},{"key":"pgph.0006039.ref018"},{"key":"pgph.0006039.ref019","volume-title":"Niger Population Census Data","author":"Institut National de la Statistique du Niger","year":"2021"},{"key":"pgph.0006039.ref020","volume-title":"R\u00e9pertoire national des localit\u00e9s","year":"2012"},{"key":"pgph.0006039.ref021","article-title":"Mali shuts schools amid fuel crisis, Russia pledges emergency deliveries","author":"A Agbetiloye","year":"2025","journal-title":"Business Insider Africa"},{"issue":"1","key":"pgph.0006039.ref022","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13063-022-06966-7","article-title":"Testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1-11-month-old infants in Mali (LAKANA): study protocol for a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial","volume":"24","author":"L Adubra","year":"2023","journal-title":"Trials"},{"key":"pgph.0006039.ref023","doi-asserted-by":"crossref","DOI":"10.1093\/inthealth\/ihad086","article-title":"Treatment coverage of mass administration of azithromycin among children aged 1-11 months in 21 districts of Kebbi state, Nigeria","volume":"15","author":"T Wamyil-Mshelia","year":"2023","journal-title":"Int Health"},{"issue":"7","key":"pgph.0006039.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003426","article-title":"Feasibility and acceptability of integrating mass distribution of azithromycin to children 1-11 months into a trachoma mass drug administration campaign to reduce child mortality in C\u00f4te d\u2019Ivoire","volume":"4","author":"L Dulli","year":"2024","journal-title":"PLOS Glob Public Health"},{"issue":"8","key":"pgph.0006039.ref025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067581","article-title":"Antenatal, intrapartum and infant azithromycin to prevent stillbirths and infant deaths: study protocol for SANTE, a 2\u00d72 factorial randomised controlled trial in Mali","volume":"13","author":"AJ Driscoll","year":"2023","journal-title":"BMJ Open"},{"issue":"15","key":"pgph.0006039.ref026","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJMoa2504644","article-title":"Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality","volume":"393","author":"FC Haidara","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"pgph.0006039.ref027","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2025-021336","article-title":"Integration of azithromycin mass administration to 1-11-month-old children into an existing health platform to reduce child mortality: a cluster-randomised trial in Burkina Faso","volume":"11","author":"F Yago-Wienne","year":"2026","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pgph.0006039.ref028","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13063-026-09561-2","article-title":"Azithromycin mass drug administration to reduce child mortality in Niger (AVENIR II): a master protocol for a cluster-randomized adaptive platform trial to evaluate community-based health interventions","volume":"27","author":"AM Arzika","year":"2026","journal-title":"Trials"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:48:52Z","timestamp":1782496132000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006039"}},"subtitle":[],"editor":[{"given":"Abraham D.","family":"Flaxman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0006039","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}